CASI Closes Patient Enrollment in Study of ENMD-2076 for Triple-Negative Breast Cancer

CASI Closes Patient Enrollment in Study of ENMD-2076 for Triple-Negative Breast Cancer
CASI Pharmaceuticals has closed enrollment in its Phase 2 clinical trial of ENMD-2076 for previously treated locally advanced or metastatic triple-negative breast cancer (TNBC). The 41 American patients it has enrolled so far are enough for the study (NCT01639248), CASI said. It continues to enroll patients in an arm of the trial in China, however. University of Colorado

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *